<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22808" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Drug-Induced Hepatotoxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Francis </surname>
            <given-names>Pilin</given-names>
          </name>
          <aff>Einstein Healthcare Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Navarro</surname>
            <given-names>Victor J.</given-names>
          </name>
          <aff>Sidney Kimmel Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pilin Francis declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Victor Navarro declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>9</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22808.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Drug-induced hepatotoxicity is an acute or chronic liver injury secondary to drugs or herbal compounds. It is difficult to diagnose because the presentation is similar to many hepatobiliary disorders. The principle treatment is the removal of the offending agent and close observation for resolution. This activity explains the pathophysiology, evaluation, and treatment of drug-induced hepatotoxicity. Additionally, it reviews the role of the interprofessional team in improving care for patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the evaluation of suspected drug-induced hepatotoxicity.</p></list-item><list-item><p>Outline the classification of drug induced hepatotoxicity based on clinical presentation, mechanism of toxicity, and histological appearance.</p></list-item><list-item><p>Identify the etiologies of drug-induced hepatotoxicity.</p></list-item><list-item><p>Summarize the importance of improving care coordination among the interdisciplinary team to enhance the delivery of care for patients with drug-induced hepatotoxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22808&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22808">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22808.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Drug-induced hepatotoxicity or drug-induced liver injury (DILI) is an acute or chronic response to a natural or manufactured compound.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref>&#x000a0;DILI can be classified based on clinical presentation (hepatocellular, cholestatic, or mixed), mechanism of hepatotoxicity, or histological appearance from a liver biopsy. The true incidence is difficult to estimate, yet it has become the leading cause of acute liver failure (ALF) in the United States. The 2 mechanisms of hepatotoxicity are intrinsic, dose-dependent, and idiosyncratic, which is more unpredictable.<xref ref-type="bibr" rid="article-22808.r2">[2]</xref><xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;Most cases of DILI are asymptomatic; however, the most common sign is jaundice.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r5">[5]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref>&#x000a0;Laboratory tests in hepatocellular injury will have elevation in aminotransferases, while in cholestatic injury, alkaline phosphatase (ALP) is elevated. A liver biopsy is not mandatory for diagnosis but could exclude other causes of liver disease. Treatment begins with the removal of the offending agent, and the prognosis for recovery is usually favorable after discontinuation of the drug.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref></p>
      </sec>
      <sec id="article-22808.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>There are patient risk factors associated with the development of DILI, which include female sex, older age, and increased body mass index (BMI).<xref ref-type="bibr" rid="article-22808.r8">[8]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref>&#x000a0;More than 1000 medications and herbal compounds are known to cause hepatotoxicity and can be found on a searchable database maintained by the National Institute of Diabetes and Digestive, and Kidney Diseases (NIDDK) called LiverTox.<xref ref-type="bibr" rid="article-22808.r10">[10]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref>&#x000a0;Intrinsic DILI is most commonly caused by acetaminophen, while it is less often seen in aspirin, tetracycline, and vitamin A <xref ref-type="bibr" rid="article-22808.r3">[3]</xref>.</p>
        <p>Idiosyncratic DILI cases are caused by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antibiotics (45.4%): amoxicillin-clavulanate (most common), sulfamethoxazole-trimethoprim, ciprofloxacin, isoniazid (INH)</p>
          </list-item>
          <list-item>
            <p>Nonsteroidal anti-inflammatory drugs (NSAIDs)</p>
          </list-item>
          <list-item>
            <p>Herbal and dietary supplements (16.1%): green tea extract, anabolic steroids, multi-ingredient nutritional supplements</p>
          </list-item>
          <list-item>
            <p>Cardiovascular drugs (10%): statins, amiodarone</p>
          </list-item>
          <list-item>
            <p>Central nervous system (CNS) agents: valproate, phenytoin</p>
          </list-item>
          <list-item>
            <p>Antineoplastic drugs: tyrosine kinase inhibitors, tumor necrosis factor inhibitors, alpha inhibitors, methotrexate&#x000a0;<xref ref-type="bibr" rid="article-22808.r2">[2]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22808.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The true incidence of DILI is difficult to determine as it is often underreported, and several different diagnostic criteria are used.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;In the United States (US) and worldwide, DILI annual incidence in the general population is under 15 to 20 per 100,000.<xref ref-type="bibr" rid="article-22808.r2">[2]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref><xref ref-type="bibr" rid="article-22808.r11">[11]</xref>&#x000a0;In the US, it is the most common cause of acute liver failure episodes (13%-16%), yet it is important to note that it is still a much less common etiology of acute liver injury overall.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref>&#x000a0;The incidence of idiosyncratic DILI is higher in women (59%) when compared to men, which may be due to hormonal interactions with immunomodulating drugs or differing pharmacokinetics. Patients more than 50 years old are more likely to develop DILI, possibly due to increased prescription drug use.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref></p>
      </sec>
      <sec id="article-22808.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of DILI can be divided into 2 mechanisms: intrinsic and idiosyncratic. The intrinsic mechanism is both predictable and reproducible from drugs that are known to cause liver injury in a dose-dependent manner with a short latency period.<xref ref-type="bibr" rid="article-22808.r7">[7]</xref><xref ref-type="bibr" rid="article-22808.r12">[12]</xref><xref ref-type="bibr" rid="article-22808.r13">[13]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref>&#x000a0;For example, in acetaminophen toxicity, the drug's metabolite leads to the production of reactive metabolites that excessively accumulate, causing apoptosis and necrosis of the hepatocytes.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r8">[8]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r1">[1]</xref><xref ref-type="bibr" rid="article-22808.r15">[15]</xref><xref ref-type="bibr" rid="article-22808.r16">[16]</xref>&#x000a0;The idiosyncratic mechanism of DILI is characterized by a more unpredictable course and is not reproducible. It occurs in susceptible patients, usually independent of the drug dose, with a variable latency period generally beginning 7 to 14 days after first ingestion.<xref ref-type="bibr" rid="article-22808.r7">[7]</xref><xref ref-type="bibr" rid="article-22808.r13">[13]</xref><xref ref-type="bibr" rid="article-22808.r12">[12]</xref>&#x000a0;Although the exact mechanism is unknown, it is thought to be due to a combination of host, drug, and environmental factors. The host factors are patient age, gender, genetic polymorphisms, immune status, and metabolism. Drug factors include the dose, duration, weight, and degree of lipophilicity. Environmental factors consist of concomitant alcohol use, diet, tobacco, and toxins.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r13">[13]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref>&#x000a0;Idiosyncratic DILI mechanisms can be divided into immune-mediated (allergic) liver injury from hypersensitivity or non-immune-mediated metabolic (non-allergic) mechanisms from mitochondrial injury.<xref ref-type="bibr" rid="article-22808.r12">[12]</xref></p>
      </sec>
      <sec id="article-22808.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Although liver biopsy is not required for diagnosis, drug-induced hepatotoxicity can be classified based on histologic findings. The histological appearance can also assist in identifying an etiology, excluding other diagnoses, and thus drive management. It is also a tool that can assist in prognostication.<xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref><xref ref-type="bibr" rid="article-22808.r13">[13]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r17">[17]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Acute hepatocellular injury: severe inflammation with necrosis and apoptosis seen in isoniazid (INH), aspirin, and phenytoin</p>
          </list-item>
          <list-item>
            <p>Chronic hepatocellular injury: findings as above with fibrosis resembling other chronic liver disease seen in amoxicillin-clavulanate, valproic acid, amiodarone</p>
          </list-item>
          <list-item>
            <p>Acute cholestasis: bile plugging with hepatocellular cholestasis, commonly seen in anabolic steroid use</p>
          </list-item>
          <list-item>
            <p>Chronic cholestasis: bile stasis, portal inflammation, bile jury, bile plugs, and duct paucity seen in amoxicillin-clavulanate</p>
          </list-item>
          <list-item>
            <p>Steatosis: microvesicular often related to mitochondrial injury seen in tetracycline and valproic acid</p>
          </list-item>
          <list-item>
            <p>Zonal necrosis: usually in intrinsic DILI and associated with poor outcomes, seen in acetaminophen toxicity</p>
          </list-item>
          <list-item>
            <p>Granulomas: associated with milder injury and can result from many drugs or even talc exposure through the bloodstream</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22808.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical presentations in drug-induced hepatotoxicity are varied and, most times, can be asymptomatic.<xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r5">[5]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref>&#x000a0;DILI manifests most commonly as jaundice, then weakness, abdominal pain, dark stools or urine, nausea, and pruritis (usually seen in cholestatic liver injury). DILI can present as acute or chronic liver failure, which makes it very difficult to distinguish from other liver conditions.<xref ref-type="bibr" rid="article-22808.r18">[18]</xref>&#x000a0;In immune-mediated hepatotoxicity, patients may present with fever, rash, eosinophilia, and even Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;The patient&#x02019;s history will reveal signs or symptoms that develop within 3 to 6 months of exposure to the offending agent; thus, a thorough medication history is of paramount importance. On physical exam, there may be jaundice, the presence of right upper quadrant tenderness, and sometimes hepatomegaly when liver injury leads to chronic liver disease.<xref ref-type="bibr" rid="article-22808.r6">[6]</xref></p>
      </sec>
      <sec id="article-22808.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis begins with a compatible history, known drugs, and excluding underlying liver disease. Subsequently, a high index of suspicion is required, as there are no specific tests available to diagnose DILI.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r17">[17]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r17">[17]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref>&#x000a0;Testing should include alanine aminotransaminase (ALT), aspartate transferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin, albumin, prothrombin time (PT), and international normalized ratio (INR). Other laboratory tests that could assist in diagnosis are complete blood count (CBC), electrolytes, viral serologies, and autoantibodies.<xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r19">[19]</xref>&#x000a0;The pattern of liver test abnormalities can distinguish between the types of liver injury. In hepatocellular injury, there is a marked elevation of transaminases (typically 3 times the upper limit) in comparison to the ALP level. In cholestatic injury or cholestasis, ALP is typically 3 times the upper limit of normal (ULN) compared&#x000a0;to transaminases. There also exists a mixed pattern of injury where both the aminotransferases and ALP are 3 times the ULN.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref><xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r12">[12]</xref>&#x000a0;In ALF, coagulopathy may be observed, indicating impaired liver function.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref>&#x000a0;Imaging studies such as abdominal ultrasound or MRI can be helpful in cholestatic injury to exclude other biliary tract pathology.<xref ref-type="bibr" rid="article-22808.r9">[9]</xref><xref ref-type="bibr" rid="article-22808.r20">[20]</xref>&#x000a0;Again, liver biopsy is not necessary for diagnosis but can be useful in exclusion, especially if other causes of liver disease are suspected.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref><xref ref-type="bibr" rid="article-22808.r17">[17]</xref>Emerging data exists on potential biomarkers to aid in the diagnosis or predict the progression of DILI. It has been shown that micro-RNAs are found in increased quantity in DILI, suggesting its release from damaged cells. Though this is not specific, it can be used to assess liver injury.<xref ref-type="bibr" rid="article-22808.r7">[7]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r15">[15]</xref><xref ref-type="bibr" rid="article-22808.r21">[21]</xref><xref ref-type="bibr" rid="article-22808.r15">[15]</xref><xref ref-type="bibr" rid="article-22808.r22">[22]</xref>&#x000a0;</p>
        <p>Several clinical prediction scores have also been developed to develop an objective diagnostic tool for DILI. The Roussel Uclaf Causality Assessment (RUCAM) includes risk factors, course of liver enzymes, suspected offending agents, and alternative causes into the scoring system. Using the calculated &#x0201c;R&#x0201d; score, the type of liver injury can be classified, and the likelihood of DILI can be determined.<xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r12">[12]</xref></p>
      </sec>
      <sec id="article-22808.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The principal treatment for drug-induced hepatotoxicity is the removal of the offending agent.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref>&#x000a0;N-acetyl-cysteine (NAC) is the treatment for intrinsic DILI secondary to acetaminophen toxicity, as this promotes the regeneration of glutathione, leading to the detoxification of the toxic metabolite.<xref ref-type="bibr" rid="article-22808.r1">[1]</xref>&#x000a0;The other specific therapy that is available is L-carnitine for valproic acid overdose.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref> Glucocorticoid therapy is usually used when the histological appearance of DILI resembles that of autoimmune hepatitis. For this reason, it has a limited role and usually does not change the course of recovery.<xref ref-type="bibr" rid="article-22808.r6">[6]</xref>&#x000a0;Symptomatic therapies such as bile acid sequestrants for cholestatic DILI or antihistamines for pruritis can be used with some efficacy.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref>&#x000a0;Hospital admission is required for patients with signs or symptoms of DILI progression or ALF.<xref ref-type="bibr" rid="article-22808.r7">[7]</xref>&#x000a0;If ALF is suspected, early liver transplant consideration is essential because there is high mortality with ALF.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;An important additional aspect of management is reporting cases of DILI to regulatory bodies to evaluate if the suspected drug needs to be withdrawn from the market.<xref ref-type="bibr" rid="article-22808.r9">[9]</xref></p>
      </sec>
      <sec id="article-22808.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>DILI is clinically challenging to diagnose as it can mimic any acute or chronic hepatobiliary condition.<xref ref-type="bibr" rid="article-22808.r12">[12]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Liver diseases: viral hepatitis (A, B, C, E), cytomegalovirus (CMV), Epstein-Barr virus, ischemic hepatitis, autoimmune hepatitis, Hemochromatosis, Wilson disease, non-alcoholic fatty liver disease (NAFLD), alcoholic hepatitis, Gilbert syndrome</p>
          </list-item>
          <list-item>
            <p>Biliary disease: cholangitis, choledocholithiasis, primary biliary cirrhosis, primary sclerosing cholangitis</p>
          </list-item>
          <list-item>
            <p>Malignancy: hepatocellular cancer, lymphoma, pancreaticobiliary malignancy</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22808.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The Drug-Induced Liver Injury Network was developed to advance research in DILI through a prospective clinical trial of patients. It created the DILIN Causality Scoring System to understand better the etiology, pathogenesis, risk factors, and outcomes of drug-induced hepatotoxicity.<xref ref-type="bibr" rid="article-22808.r2">[2]</xref><xref ref-type="bibr" rid="article-22808.r23">[23]</xref></p>
      </sec>
      <sec id="article-22808.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Generally, patients have a favorable prognosis after discontinuing the offending drug, as 90% recover. Mortality risk can be predicted through &#x0201c;Hy&#x02019;s law,&#x0201d; which includes the following criteria that are associated with a poorer prognosis: ALT/AST more than 3 times ULN, total bilirubin up to 2 times ULN in the absence of obstruction, and no other explanation of the mentioned laboratory values.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref>&#x000a0;Individuals 65 years and older had a higher incidence of Hy&#x02019;s law; however, mortality does not differ.<xref ref-type="bibr" rid="article-22808.r2">[2]</xref>&#x000a0;Hepatocellular injury is more likely than cholestatic injury to have a 10% to 50% higher risk of mortality or to require a liver transplant.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref><xref ref-type="bibr" rid="article-22808.r9">[9]</xref>&#x000a0;In general, about 10% of patients progress to requiring liver transplantation. Following liver transplantation, survival is 66%.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref></p>
      </sec>
      <sec id="article-22808.s13" sec-type="Complications">
        <title>Complications</title>
        <p>There is a 17% risk of progression to chronic liver disease, mostly seen in patients with prolonged cholestatic injury such as vanishing duct syndrome.<xref ref-type="bibr" rid="article-22808.r2">[2]</xref><xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;Acute liver failure results more often from hepatocellular injury than cholestatic.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r14">[14]</xref></p>
      </sec>
      <sec id="article-22808.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Prevention of DILI can begin with patient education on their medications, which include over-the-counter drugs, prescription medications, and herbal and dietary supplements. If patients should experience signs and symptoms of liver toxicity or ALF, further evaluation is required.</p>
      </sec>
      <sec id="article-22808.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>More than 1000 medications and herbal compounds can cause drug-induced hepatotoxicity.<xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r10">[10]</xref>Patients can present with symptoms that manifest similarly to other hepatobiliary disorders. Thus, it is important to perform a thorough drug history when drug-induced hepatotoxicity is suspected.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r6">[6]</xref><xref ref-type="bibr" rid="article-22808.r17">[17]</xref><xref ref-type="bibr" rid="article-22808.r3">[3]</xref>&#x000a0;Once DILI is suspected as the likely etiology of hepatotoxicity, remove the offending agent and monitor for signs of ALF, as transplantation evaluation is necessary.<xref ref-type="bibr" rid="article-22808.r3">[3]</xref><xref ref-type="bibr" rid="article-22808.r4">[4]</xref><xref ref-type="bibr" rid="article-22808.r7">[7]</xref>&#x000a0;A multidisciplinary approach with clinicians, pharmacists, and nurses is required to diagnosis and report suspected drugs to regulatory organizations to assess their potential removal from the market.<xref ref-type="bibr" rid="article-22808.r9">[9]</xref>&#x000a0;A web-based resource can aid healthcare providers in this. It contains a&#x000a0;database of&#x000a0;offending compounds with a description of their liver toxicity, and there is also a case submission registry that allows users to report DILI cases directly;&#x000a0;this can then be forwarded to the US Food and Drug Administration's Event Reporting System.<xref ref-type="bibr" rid="article-22808.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22808.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22808&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22808">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/drug-induced-hepatotoxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22808">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22808/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22808">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22808.s17">
        <title>References</title>
        <ref id="article-22808.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fisher</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vuppalanchi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saxena</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>139</volume>
            <issue>7</issue>
            <fpage>876</fpage>
            <page-range>876-87</page-range>
            <pub-id pub-id-type="pmid">26125428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Talwalkar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <collab>United States Drug Induced Liver Injury Network</collab>
            </person-group>
            <article-title>Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.</article-title>
            <source>Gastroenterology</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>148</volume>
            <issue>7</issue>
            <fpage>1340</fpage>
            <page-range>1340-52.e7</page-range>
            <pub-id pub-id-type="pmid">25754159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katarey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury.</article-title>
            <source>Clin Med (Lond)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>Suppl 6</issue>
            <fpage>s104</fpage>
            <page-range>s104-s109</page-range>
            <pub-id pub-id-type="pmid">27956449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuna</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bozic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kizivat</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bojanic</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mrso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kralj</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Smolic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Smolic</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.</article-title>
            <source>Curr Drug Metab</source>
            <year>2018</year>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>830</fpage>
            <page-range>830-838</page-range>
            <pub-id pub-id-type="pmid">29788883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <collab>Practice Parameters Committee of the American College of Gastroenterology</collab>
            </person-group>
            <article-title>ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>109</volume>
            <issue>7</issue>
            <fpage>950</fpage>
            <page-range>950-66; quiz 967</page-range>
            <pub-id pub-id-type="pmid">24935270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rnsson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seeff</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Liver injury from herbal and dietary supplements.</article-title>
            <source>Hepatology</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>363</fpage>
            <page-range>363-373</page-range>
            <pub-id pub-id-type="pmid">27677775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tujios</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
            </person-group>
            <article-title>Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy.</article-title>
            <source>Liver Int</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-14</page-range>
            <pub-id pub-id-type="pmid">28771932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Njoku</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced hepatotoxicity: metabolic, genetic and immunological basis.</article-title>
            <source>Int J Mol Sci</source>
            <year>2014</year>
            <month>Apr</month>
            <day>22</day>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>6990</fpage>
            <page-range>6990-7003</page-range>
            <pub-id pub-id-type="pmid">24758937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Real</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barnhill</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Higley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Liver Injury: Highlights of the Recent Literature.</article-title>
            <source>Drug Saf</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>365</fpage>
            <page-range>365-387</page-range>
            <pub-id pub-id-type="pmid">30343418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2012</year>
            <pub-id pub-id-type="pmid">31643176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suk</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver injury: present and future.</article-title>
            <source>Clin Mol Hepatol</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>249</fpage>
            <page-range>249-57</page-range>
            <pub-id pub-id-type="pmid">23091804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teschke</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>730</fpage>
            <pub-id pub-id-type="pmid">31396080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.</article-title>
            <source>Gastroenterology</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>146</volume>
            <issue>4</issue>
            <fpage>914</fpage>
            <page-range>914-28</page-range>
            <pub-id pub-id-type="pmid">24389305</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robles-D&#x000ed;az</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medina-Caliz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lucena</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Biomarkers in DILI: One More Step Forward.</article-title>
            <source>Front Pharmacol</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>267</fpage>
            <pub-id pub-id-type="pmid">27597831</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teschke</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Danan</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Molecular Research on Drug Induced Liver Injury.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Jan</month>
            <day>11</day>
            <volume>19</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">29324638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Au</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Review article: Drug-induced liver injury--its pathophysiology and evolving diagnostic tools.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-20</page-range>
            <pub-id pub-id-type="pmid">21539586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Davern</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Talwalkar</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
              <collab>Drug-Induced Liver Injury Network (DILIN)</collab>
            </person-group>
            <article-title>Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations.</article-title>
            <source>Hepatology</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>661</fpage>
            <page-range>661-70</page-range>
            <pub-id pub-id-type="pmid">24037963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shehu</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Drug-Induced Hepatotoxicity.</article-title>
            <source>Clin Liver Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-54</page-range>
            <pub-id pub-id-type="pmid">27842774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Tillmann</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cloherty</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Hoofnagle</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Importance of Hepatitis C Virus RNA Testing in Patients with Suspected Drug-Induced Liver Injury.</article-title>
            <source>Dig Dis Sci</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>64</volume>
            <issue>9</issue>
            <fpage>2645</fpage>
            <page-range>2645-2652</page-range>
            <pub-id pub-id-type="pmid">30927209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ghabril</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Barnhart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kleiner</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bjornsson</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>Sclerosing Cholangitis-Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury.</article-title>
            <source>Clin Gastroenterol Hepatol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>789</fpage>
            <page-range>789-790</page-range>
            <pub-id pub-id-type="pmid">29966706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howell</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Ireland</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Goldring</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury.</article-title>
            <source>Expert Rev Mol Diagn</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-54</page-range>
            <pub-id pub-id-type="pmid">29235390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnhill</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Real</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Latest advances in diagnosing and predicting DILI: what was new in 2017?</article-title>
            <source>Expert Rev Gastroenterol Hepatol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>1033</fpage>
            <page-range>1033-1043</page-range>
            <pub-id pub-id-type="pmid">30111182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22808.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontana</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Watkins</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bonkovsky</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Chalasani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davern</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rochon</surname>
                <given-names>J</given-names>
              </name>
              <collab>DILIN Study Group</collab>
            </person-group>
            <article-title>Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.</article-title>
            <source>Drug Saf</source>
            <year>2009</year>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-68</page-range>
            <pub-id pub-id-type="pmid">19132805</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
